NDA 209607 · Progenics Pharms INC
Azedra
Iobenguane I-131 · Intravenous
Breakthrough therapyPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 30, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
36
3 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 2018 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
- AZEDRA · IOBENGUANE I-131 15mCi/ML · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Iobenguane I-131" as an intervention, any sponsor and status, largest first.
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With NeuroblastomaPivotal-lookingStatus unknown
German Society for Pediatric Oncology and Hematology GPOH gGmbHAcademic, hospital or other
NCT00410631 · 642 participants (planned) · Start Oct 2004 · Primary completion Dec 2010
Drug: filgrastim; carboplatin and 11 more · For: Neuroblastoma
Sites: Aachen, Germany; Augsburg, Germany; Bamberg, Germany · 80 sites in all
- Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk NeuroblastomaPivotal-lookingStatus unknown
German Society for Pediatric Oncology and Hematology GPOH gGmbHAcademic, hospital or other
NCT00526318 · 360 participants (planned) · Start Jan 2007 · Primary completion Dec 2016
Drug: filgrastim; carboplatin and 11 more · For: Neuroblastoma
Sites: Aachen, Germany; Augsburg, Germany; Bayreuth, Germany · 68 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT00107289 · 200 participants (planned) · Start May 2006 · Primary completion May 2027
Drug: iobenguane I 131 · For: Neuroblastoma; Pheochromocytoma
Sites: New York, New York
University of California, San FranciscoAcademic, hospital or other
NCT00293319 · 164 participants · Start Apr 2005 · Primary completion Mar 2006
Drug: filgrastim · For: Neuroblastoma
Sites: San Francisco, California; Ann Arbor, Michigan; Philadelphia, Pennsylvania
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabPivotal-lookingNot yet recruiting
New Approaches to Neuroblastoma Therapy ConsortiumAcademic, hospital or other
NCT07261241 · 118 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2030
Drug: Radiation: 131I-MIBG; Dinutuximab and 1 more · For: Neuroblastoma
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 13 sites in all
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With VorinostatPivotal-lookingCompleted
New Approaches to Neuroblastoma Therapy ConsortiumAcademic, hospital or other
NCT02035137 · 114 participants · Start Jul 2014 · Primary completion Feb 26, 2021
Drug: Vincristine; Irinotecan and 1 more · For: Neuroblastoma
Sites: Los Angeles, California; Palo Alto, California; San Francisco, California · 14 sites in all
Children's Oncology GroupResearch network
NCT01175356 · 99 participants · Start Dec 21, 2011 · Primary completion Sep 28, 2016
Drug: Busulfan; Cisplatin and 7 more · For: Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE, Stubbs JB, Barrett JA, et al. · Cancer Biother Radiopharm 2009 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Progenics Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.